Drug Trial Radar · NCT03371979
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
42
Actual
Start
Dec 21, 2017
Primary completion
Jun 11, 2020
Study completion Jun 11, 2020
Sponsor
- Lead sponsor
- Immedica Pharma ABIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC; Aeglea Biotherapeutics
- First posted
- Dec 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
Conditions
- Small-cell Lung Cancer
Interventions
PegzilarginaseDrug
Administered IV
PembrolizumabDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of Treatment-realted Adverse Events as Assessed by CTCAE v4.0Time frame: Estimated up to 6 months
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama, Mitchell Cancer Institute
Mobile, Alabama
University of Colorado
Aurora, Colorado
Rocky Mountain Cancer Centers
Denver, Colorado
Mid Florida Hematology and Oncology Centers
Orange City, Florida
Woodlands Medical Specialists, PA
Pensacola, Florida
Moffitt Cancer Center
Tampa, Florida
Emory University
Atlanta, Georgia
University of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Washington University
St Louis, Missouri
Nebraska Cancer Specialists
Omaha, Nebraska
The Valley Hospital, Luckow Pavilion
Paramus, New Jersey
Oncology Hematology Care Inc.
Cincinnati, Ohio
Providence Cancer Center
Portland, Oregon
UPMC Cancer Center
Pittsburgh, Pennsylvania
Charleston Hematology Oncology Associates
Charleston, South Carolina
West Clinic
Germantown, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology-Memorial City
Houston, Texas
Texas Oncology-Tyler
Tyler, Texas
Oncology & Hematology Associates of SW Virginia
Blacksburg, Virginia
Fundacion De Investigacion, Hematology/Oncology
San Juan, Puerto Rico, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.